Positive. William Blair initiates bullish coverage on Ocular Therapeutix, praising potential of lead asset Axpaxli

From Financial Modeling Prep: 2025-04-08 16:21:00

William Blair has initiated coverage on Ocular Therapeutix with an Outperform rating and a fair value target of $18 per share. The biotech’s lead asset, Axpaxli, is a sustained-release hydrogel implant undergoing Phase III trials for nAMD. This long-acting therapeutic approach could revolutionize nAMD treatment, offering improved efficacy and durability.

Axpaxli, part of the TKI class, aims to reduce the need for frequent injections, potentially becoming best-in-class in nAMD treatment. William Blair is optimistic about the expansion of Axpaxli’s use beyond nAMD into other retinal vascular diseases, presenting a significant long-term opportunity for Ocular Therapeutix.



Read more at Financial Modeling Prep:: Ocular Therapeutix Gets Bullish Coverage at Willia…